Literature DB >> 11830511

Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.

Osamu Ishimoto1, Chikashi Kawahara, Kentaro Enjo, Masuo Obinata, Toshihiro Nukiwa, Shuntaro Ikawa.   

Abstract

p73, a recently identified gene highly homologous to p53, can transactivate p53 target genes and induce apoptosis. Here we report the identification of an NH(2)-terminal truncated isoform of human p73, DeltaNp73, which is capable of suppressing p53- and p73-dependent transactivation. We speculate that this suppression is achieved by competing for the DNA binding site in the case of p53 and by direct association in the case of TAp73. Expression of DeltaNp73 in cancer cell lines also inhibited suppressive activity of p53 and TAp73 in colony formation, implying possible involvement of DeltaNp73 in oncogenesis by inhibiting the tumor-suppressive function of p53 and TAp73. Also reported is the identification of TAp73eta, a new member of the COOH-terminal truncated isoform of p73 and tissue-specific expression of these isoforms, along with other previously identified p73 isoforms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11830511

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

1.  DeltaNp73beta is active in transactivation and growth suppression.

Authors:  Gang Liu; Susan Nozell; Hui Xiao; Xinbin Chen
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

2.  How many mutant p53 molecules are needed to inactivate a tetramer?

Authors:  Wan Mui Chan; Wai Yi Siu; Anita Lau; Randy Y C Poon
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

3.  Association of a p73 exon 2 GC/AT polymorphism with colorectal cancer risk and survival in Tunisian patients.

Authors:  Amira Toumi Arfaoui; Lilia Ben Mahmoud Kriaa; Olfa El Amine El Hadj; Majid A Ben Hmida; Myriam Khiari; T Khalfallah; Lasaad Gharbi; Sabeh Mzabi; Sadaa Bouraoui
Journal:  Virchows Arch       Date:  2010-07-20       Impact factor: 4.064

4.  Regulation of ΔNp63α by NFκΒ.

Authors:  Tanusree Sen; Xiaofei Chang; David Sidransky; Aditi Chatterjee
Journal:  Cell Cycle       Date:  2010-12-15       Impact factor: 4.534

5.  DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells.

Authors:  A P Simões-Wüst; B Sigrist; L Belyanskaya; S Hopkins Donaldson; R A Stahel; U Zangemeister-Wittke
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

Review 6.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

7.  SIRT2-mediated inactivation of p73 is required for glioblastoma tumorigenicity.

Authors:  Kosuke Funato; Tomoatsu Hayashi; Kanae Echizen; Lumi Negishi; Naomi Shimizu; Ryo Koyama-Nasu; Yukiko Nasu-Nishimura; Yasuyuki Morishita; Viviane Tabar; Tomoki Todo; Yasushi Ino; Akitake Mukasa; Nobuhito Saito; Tetsu Akiyama
Journal:  EMBO Rep       Date:  2018-09-13       Impact factor: 8.807

Review 8.  Therapeutic prospects for p73 and p63: rising from the shadow of p53.

Authors:  Anna Vilgelm; Wael El-Rifai; Alexander Zaika
Journal:  Drug Resist Updat       Date:  2008-09-17       Impact factor: 18.500

9.  U-box-type ubiquitin E4 ligase, UFD2a attenuates cisplatin mediated degradation of DeltaNp63alpha.

Authors:  Aditi Chatterjee; Sunil Upadhyay; Xiaofei Chang; Jatin K Nagpal; Barry Trink; David Sidransky
Journal:  Cell Cycle       Date:  2008-02-19       Impact factor: 4.534

10.  BUB3 that dissociates from BUB1 activates caspase-independent mitotic death (CIMD).

Authors:  Y Niikura; H Ogi; K Kikuchi; K Kitagawa
Journal:  Cell Death Differ       Date:  2010-01-08       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.